A Study of LY3471851 in Adults With Systemic Lupus Erythematosus (SLE)
ISLAND-SLE
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of LY3471851 (NKTR-358) in Adults With Systemic Lupus Erythematosus
3 other identifiers
interventional
291
19 countries
112
Brief Summary
The reason for this study is to see if the study drug LY3471851 (NKTR-358) is safe and effective in adults with systemic lupus erythematosus (SLE).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_2
Started Aug 2020
112 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 15, 2020
CompletedFirst Posted
Study publicly available on registry
June 16, 2020
CompletedStudy Start
First participant enrolled
August 19, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 10, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
February 16, 2023
CompletedResults Posted
Study results publicly available
April 23, 2024
CompletedApril 23, 2024
March 1, 2024
2.4 years
June 15, 2020
March 27, 2024
March 27, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Percentage of Participants Who Achieved a ≥4 Point Reduction in Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) 2000 (2K) Score at Week 24
Percentage of Participants who Achieved a ≥4 Point Reduction in SLEDAI-2K Score at Week 24. A SLEDAI-4 response is defined as a ≥4-point reduction in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score from baseline. The SLEDAI-2K score range is from a minimum of 0 to a maximum of 105 (higher scores represent higher disease activity).
Week 24
Secondary Outcomes (4)
Percentage of Participants Who Achieved British Isles Lupus Assessment Group (BILAG) Based Composite Lupus Assessment (BICLA) Response at Week 24.
Week 24
Percentage of Participants Who Achieved Systemic Lupus Erythematosus Responder Index 4 (SRI-4) Response at Week 24
Week 24
Percentage of Participants Who Achieved Lupus Low Disease Activity State (LLDAS) at Week 24
Week 24
Pharmacokinetics (PK): Trough Concentrations (Ctrough) of LY3471851
Week 24
Study Arms (4)
LY3471851 High Dose
EXPERIMENTALLY3471851 administered subcutaneously (SC).
LY3471851 Mid Dose
EXPERIMENTALLY3471851 administered SC.
LY3471851 Low Dose
EXPERIMENTALLY3471851 administered SC
Placebo
PLACEBO COMPARATORPlacebo administered SC.
Interventions
Eligibility Criteria
You may qualify if:
- Have a clinical diagnosis of SLE at least 24 weeks prior to screening.
- Have documentation of having met at least 4 of 11 Revised Criteria for Classification of Systemic Lupus Erythematosus according to the 1997 Update of the 1982 American College of Rheumatology (ACR) criteria for classification of SLE prior to randomization.
- Have a positive antinuclear antibody (ANA) (titer ≥1:80) and/or a positive anti-double-stranded deoxyribonucleic acid (dsDNA), and/or a positive anti-Smith (anti-Sm) as assessed by a central laboratory during screening.
- Have a total Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score ≥6 during screening.
- Have a clinical SLEDAI-2K score ≥4 at randomization.
- Have active arthritis and/or active rash.
You may not qualify if:
- Have severe active lupus nephritis.
- Have active central nervous system (CNS) lupus.
- Have a history or presence of cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, hematological, neurological, or neuropsychiatric disorders or any other serious and/or unstable illness that, in the opinion of the investigator, could constitute an unacceptable risk when taking investigational product or interfere with the interpretation of data.
- Have a current or recent clinically serious viral, bacterial, fungal, or parasitic infection.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Nektar Therapeuticslead
- Eli Lilly and Companycollaborator
Study Sites (112)
University of California - San Diego
La Jolla, California, 92037, United States
Desert Medical Advances
Palm Desert, California, 92260, United States
Stanford University Hospital
Stanford, California, 94305, United States
Inland Rheumatology & Osteoporosis Medical Group
Upland, California, 91786, United States
University of Colorado School of Medicine
Aurora, Colorado, 80045, United States
Clinical Research Center of CT/NY
Danbury, Connecticut, 06810, United States
Yale University School of Medicine
New Haven, Connecticut, 06519, United States
Stamford Therapeutics Consortium
Stamford, Connecticut, 06905, United States
University of Miami School of Medicine
Miami, Florida, 33136, United States
New Horizon Research Center
Miami, Florida, 33165 3338, United States
NECCR PrimaCare Research
Fall River, Massachusetts, 02721, United States
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Northwell Health
Great Neck, New York, 11021, United States
NYU Langone
New York, New York, 10016, United States
MetroHealth Medical Center
Cleveland, Ohio, 44109, United States
Paramount Medical Research
Middleburg Heights, Ohio, 44130, United States
Oklahoma Medical Research Foundation
Oklahoma City, Oklahoma, 73104-5046, United States
Accurate Clinical Management
Baytown, Texas, 77521, United States
Metroplex Clinical Research Center
Dallas, Texas, 75231, United States
University of Texas Southwestern Medical Center at Dallas
Dallas, Texas, 75390, United States
Accurate Clinical Research
Houston, Texas, 77089, United States
Fort Bend Clinical Research, LLC
Sugar Land, Texas, 77479, United States
University of Washington Medical Center
Seattle, Washington, 98195-6422, United States
DOM- Centro de Reumatologia
CABA, Buenos Aires, 1111, Argentina
Centro Privado de Medicina Familiar / Mindout Research
Ciudad Autónoma de Buenos Aire, Buenos Aires, 1417, Argentina
APRILLUS Asistencia E Investigacion de Arcis Salud
CABA, Ciudad Autónoma de Buenos Aire, 1406, Argentina
Clinica Adventista Belgrano
CABA, Ciudad Autónoma de Buenos Aire, C1430EGF, Argentina
Centro de Investigaciones Médicas Tucuman
SAN M. de Tucuman, Tucumán Province, T4000AXL, Argentina
Hospital J. M. Ramos Mejía
Ciudad Autónoma de Buenos Aire, C1221ADC, Argentina
Hospital Córdoba
Córdoba, 5004, Argentina
Centro Polivalente de Asistencia e Inv. Clinica CER-San Juan
San Juan, J5402DIL, Argentina
Emeritus Research
Camberwell, Victoria, 3124, Australia
University of Calgary
Calgary, Alberta, T2N 4N1, Canada
INREA s.r.o.
Ostrava, Ostrava Město, 70300, Czechia
Revmatologicky ustav
Prague, Praha, Hlavní Mešto, 12850, Czechia
Universitätsklinikum Tübingen
Tübingen, Baden-Wurttemberg, 72076, Germany
Universtitätsklinikum Essen AöR
Essen, North Rhine-Westphalia, 45147, Germany
Rheumazentrum Ruhrgebiet
Herne, North Rhine-Westphalia, 44649, Germany
Klinikum Bad Bramstedt GmbH
Bad Bramstedt, Schleswig-Holstein, 24576, Germany
Universitätsklinikum Köln
Cologne, 50924, Germany
Klinik für Innere Medizin I, Universitätsklinikum Schleswig-Holstein, Campus Kiel
Kiel, 24105, Germany
Békés Megyei Központi Kórház Pándy Kálmán Tagkórház
Gyula, Bekes County, 5700, Hungary
Qualiclinic
Budapest, 1036, Hungary
Debreceni Egyetem Orvos-es Egészsegtudomanyi Centrum
Debrecen, 4004, Hungary
Krishna Institute of Medical Science
Hyderabad, Andhra Pradesh, 500003, India
King George Hospital
Visakhapatanam, Andhra Pradesh, 530002, India
Amber Clinic
Ahmedabad, Gujarat, 380015, India
Swastik Rheumatology Clinic
Ahmedabad, Gujarat, 380054, India
Sushruta Multispeciality Hospital & Research Centre
Hubli, Karnataka, 580021, India
Government Medical College (GMC) Aurangabad
Aurangabad, Maharashtra, 431001, India
Government Medical College
Nagpur, Maharashtra, 440003, India
Jasleen Hospital
Nagpur, Maharashtra, 440012, India
All India Institute of Medical Sciences - Nagpur
Nagpur, Maharashtra, 441108, India
Sancheti Institute for Orthopaedics & Rehabilitation
Pune, Maharashtra, 41005, India
Center for Rheumatic Diseases
Pune, Maharashtra, 411001, India
Sancheti HealthCare Academy
Pune, Maharashtra, 411005, India
Sir Ganga Ram Hospital
New Delhi, National Capital Territory of Delhi, 110060, India
Sheba Medical Center
Ramat Gan, Central District, 5262100, Israel
Rambam Medical Center
Haifa, 3109601, Israel
Meir Medical Center
Kfar Saba, 4428164, Israel
Tel Aviv Sourasky Medical Center
Tel Aviv, 6423906, Israel
Kojunkai Daido Clinic
Nagoya, Aichi-ken, 4570818, Japan
University of Occupational and Enviromental Health
Kitakyushu, Fukuoka, 807-8556, Japan
Hokkaido University Hospital
Sapporo, Hokkaido, 060-8648, Japan
Tohoku University Hospital
Sendai, Miyagi, 980-8574, Japan
Shinshu University Hospital
Matsumoto, Nagano, 390-8621, Japan
Sasebo Chuo Hospital
Sasebo, Nagasaki, 857-1195, Japan
National Hospital Organization Chibahigashi National Hospital
Chiba, 260-8712, Japan
National Hospital Organization Kyushu Medical Center
Fukuoka, 810 8563, Japan
Okayama University Hospital
Okayama, 700-8558, Japan
Daini Osaka Police Hospital
Osaka, 543-0042, Japan
St. Luke's International Hospital
Tokyo, 104-8560, Japan
Keio university hospital
Tokyo, 160 8582, Japan
CIMAB SA de CV
Torreón, Coahuila, 27000, Mexico
Centro Medico del Angel
Mexicali, Estado de Baja California, 21100, Mexico
Centro Integral en Reumatologia
Guadalajara, Jalisco, 44160, Mexico
Clinica de Investigacion en Reumatologia y Obesidad S. C.
Guadalajara, Jalisco, 44650, Mexico
RM Pharma Specialists S.A. de C.V.
Mexico City, Mexico City, 03100, Mexico
Clinica para el Diagnostico y Tratamiento de la Enfermedades
Mexico City, Mexico City, 06700, Mexico
MICS Centrum Medyczne Warszawa
Warsaw, Masovian Voivodeship, 00874, Poland
Nova Reuma Społka Partnerska
Bialystok, Podlaskie Voivodeship, 15-707, Poland
Nzoz Bif-Med
Bytom, Silesian Voivodeship, 41-902, Poland
Szpital Uniwersytecki Nr 2 w Bydgoszczy
Bydgoszcz, 85-168, Poland
Centro Reumatologico Caguas
Caguas, PR, 00725, Puerto Rico
Latin Clinical Trial Center
San Juan, PR, 00909, Puerto Rico
GCM Medical Group, PSC - Hato Rey Site
San Juan, PR, 00917, Puerto Rico
Mindful Medical Research
San Juan, PR, 00918, Puerto Rico
C.M.D.T.A. Neomed
Brasov, Brașov County, 500283, Romania
SC Centrul Medical Sana SRL
Bucharest, 011025, Romania
Spitalul Clinic Sf Maria Bucuresti
Bucharest, 011172, Romania
Spitalul Clinic Judetean de Urgenta Sf. Apostol Andrei
Galati, 800578, Romania
Karelia Republican Hospital V.A. Baranova
Petrozavodsk, Kareliya, Respublika, 185019, Russia
Moscow City Clinical Hospital Number 15
Moscow, Moscow, 111539, Russia
V.A. Nasonova Research Institute of Rheumatology
Moscow, 115522, Russia
Ryazan Regional Clinical Cardiology Dispensary
Ryazan, 390026, Russia
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, 13620, South Korea
Inha University Hospital
Incheon, Korea, 22332, South Korea
Kyung Hee University Hospital
Seoul, Korea, 02447, South Korea
Hanyang University Medical Center
Seoul, Korea, 04763, South Korea
Seoul National University Hospital
Seoul, Seoul, Korea, 03080, South Korea
Hospital Universitari Vall d'Hebron
Barcelona, 08035, Spain
Hospital Quiron Infanta Luisa
Seville, 41010, Spain
Chang Gung Memorial Hospital - Kaohsiung Branch
Kaohsiung City, 83301, Taiwan
China Medical University Hospital
Taichung, 40447, Taiwan
Taichung Veterans General Hospital
Taichung, 40705, Taiwan
National Taiwan University Hospital
Taipei, 10048, Taiwan
Regional Clinical Hospital Center for Emergency medical care
Kharkiv, Ukraine
Edelweiss Medics LLC
Kyiv, 02002, Ukraine
Kyiv City Clinical Hospital #3
Kyiv, Ukraine
Multifield Medical Center of Odesa NMU (University Clinic#1)
Odesa, 65026, Ukraine
Vinnytsya Regional Clinical Hospital
Vinnytsia, 21018, Ukraine
Regional Clinical Hospital of Zaporizhzhia
Zaporizhzhia, 69600, Ukraine
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Results Point of Contact
- Title
- Study Director
- Organization
- Nektar Therapeutics
Study Officials
- STUDY DIRECTOR
Study Director
Nektar Therapeutics
Publication Agreements
- PI is Sponsor Employee
- No
- Restriction Type
- GT60
- Restrictive Agreement
- Yes
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 15, 2020
First Posted
June 16, 2020
Study Start
August 19, 2020
Primary Completion
January 10, 2023
Study Completion
February 16, 2023
Last Updated
April 23, 2024
Results First Posted
April 23, 2024
Record last verified: 2024-03
Data Sharing
- IPD Sharing
- Will not share